Sinusitis is a common disorder where the sinus linings get inflamed & disrupt the respiratory path of the patient. It is generally affected by a viral infection or dust allergies. Some signs & symptoms include a plugged nose, thick nasal mucus, and pain in the face. In addition, other signs & symptoms may include headaches, sore throat, fever, poor sense of smell, and cough.
According to study, “World Drugs for Sinusitis Market Research Report 2024(Covering North America, Europe, China, South East Asia, Japan and India)” the key companies operating in the world drugs for sinusitis market are Sanofi, AstraZeneca Plc., Abbott Laboratories, Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Novartis AG, Bionorica SE, Merck and Co. Inc., Bristol-Myers Squibb, Beximco Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Amgen, Huasun, Pfizer, Eli Lilly and Company, CHIESI Farmaceutici Spa, Intersect ENT Inc., Zydus Cadila, GlaxoSmithKline Plc. The key players are acquiring numerous small & medium scale businesses in order to increase their resource bank & production capacity. Many companies are investing heavily on research & development (R&D) activities in order to gain a technical edge over their rivals and stay ahead in the competition of the control of global sinusitis drugs market.
Based on type, sinusitis drugs market is segmented into chronic sinusitis, recurrent sinusitis, acute sinusitis and sub-acute sinusitis. Acute sinusitis starts with cold like symptoms for instance stuffy nose, a runny and facial pain. Based on product type, market is segmented into antibiotics, decongestants, corticosteroids and others. Based on age-group, market is segmented into teenagers, children and adults. Based on application, market is segmented into neurology, musculoskeletal & spine, orthopedics, skin & integumentary and cardiology & vascular. In addition, based on end-user, market is segmented into surgical centers, hospitals and pharmacy store.
The sinusitis drugs market is driven by rise in prevalence of sinusitis, followed by increase in mergers & acquisitions, growth in number of respiratory tract infection, huge development in the medical device sector, various technological advancements in healthcare sector & pharmaceuticals companies, rise in number of bacterial, fungal infections & allergic reactions, increase in investment by key players in R&D, rise in cases of chronic rhinosinusitis (CRS) and growth in awareness among people about sinusitis treatment. However, unknown etiology of sinusitis, high cost associated with drugs of sinusitis, surgical intervention for sinusitis management, and the launch of generics may impact the market. Moreover, rise in technological advancements and growth in number of chronic sinusitis patients are key opportunities for market.
Based on geography, the USA country holds major share, followed by Europe in sinusitis drugs market owing to increase in incidence of sinusitis and rise in innovative products in the country. The China and India countries are expected to witness higher growth rate due to growth in awareness among people and increase in number of bacteria & viruses infections over the forecast period. It is projected that future of the market will be bright on account of increase in demand of antibiotics and growth in development in sinusitis treatments in developed & developing economies during the forecast period. The global market is anticipated to grow at a CAGR of approximately 3.6% over the next five years, will reach US $2410 million in 2024, from US $1950 million in 2019.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications